Sugi Predict

Sugi Predict / Targets / P2RY4

P2RY4

P2Y purinoceptor 4 · P51582 · P2RY4 on Sugi Atlas →

44,164 patent compounds predicted against P2RY4, 24,799 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL725124 SCHEMBL725124 0.61 14/20
SCHEMBL29532 SCHEMBL29532 0.66 13/20
Denufosol Denufosol (SCHEMBL561652) 0.98 12/20
SCHEMBL185515 SCHEMBL185515 0.59 11/20
SCHEMBL374031 SCHEMBL374031 0.52 11/20
SCHEMBL341554 SCHEMBL341554 0.48 11/20
SCHEMBL716498 SCHEMBL716498 1.00 10/20
SCHEMBL716499 SCHEMBL716499 1.00 10/20
SCHEMBL625973 SCHEMBL625973 0.94 10/20
SCHEMBL624628 SCHEMBL624628 0.75 10/20
SCHEMBL788753 SCHEMBL788753 0.72 10/20
SCHEMBL373443 SCHEMBL373443 0.71 10/20
SCHEMBL8003 SCHEMBL8003 0.68 10/20
SCHEMBL48209 SCHEMBL48209 0.68 10/20
SCHEMBL126076 SCHEMBL126076 0.67 10/20
SCHEMBL373603 SCHEMBL373603 0.66 10/20
SCHEMBL373494 SCHEMBL373494 0.64 10/20
SCHEMBL661070 SCHEMBL661070 0.61 10/20
SCHEMBL92468 SCHEMBL92468 0.55 10/20
SCHEMBL582954 SCHEMBL582954 0.52 10/20

Clinical trials — most relevant to P2RY4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel PHASE4COMPLETED
Reversal of the Anti-platelet Effects of Ticagrelor PHASE4COMPLETED
Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine PHASE4COMPLETED
Add-on Cangrelor in STEMI-triggered Cardiac Arrest PHASE4UNKNOWN
Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects PHASE4COMPLETED
Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR PHASE4NOT_YET_RECRUITING
Effect of Amlodipine on Anti-platelet Drug Effect in Patients With Coronary Artery Disease PHASE4COMPLETED
PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment PHASE4COMPLETED
Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease PHASE4COMPLETED
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study PHASE4COMPLETED
Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors -Trial dOPPLER- PHASE4UNKNOWN
A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function: PHASE4COMPLETED
Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease PHASE2/PHASE3COMPLETED
Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention. PHASE3WITHDRAWN
Clopidogrel and Response Variability Investigation Study 2 PHASE3COMPLETED
Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS PHASE3COMPLETED
Trimetazidine as an Adjunct to Enhance Clopidogrel Response. PHASE2COMPLETED
POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy PHASE2RECRUITING
The Impact of Genotype on Pharmacokinetics and Antiplatelet Effects of Ticagrelor in Healthy Chinese PHASE1COMPLETED
Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects PHASE1COMPLETED
Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults EARLY_PHASE1COMPLETED
Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients nanRECRUITING
Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders nanUNKNOWN
Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence nanCOMPLETED
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE) nanACTIVE_NOT_RECRUITING
Functional Magnetic Resonance Imaging of ATP Cough in Chronic Cough Patients nanCOMPLETED
Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention nanCOMPLETED
The Role of Urinary ATP in the Diagnosis, Treatment, and Follow-up of Children With Overactive Bladder nanCOMPLETED
Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes nanCOMPLETED
Identification of Clopidogrel CYP2C19 Metabolizer and Thienopyridine Treatment After an Acute Coronary Syndrome nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a P2RY4 binder may also engage these)

ProteinNameSimilarity
O35811 — 0.999 O35811 →
Q9JJS7 — 0.993 Q9JJS7 →
Q5YA25 — 0.992 Q5YA25 →
P35383 — 0.992 P35383 →
P41232 — 0.991 P41232 →
P2RY2 P2Y purinoceptor 2 0.989 landscape →
Q63371 — 0.985 Q63371 →
P2RY6 P2Y purinoceptor 6 0.984 landscape →
Q9ERK9 — 0.984 Q9ERK9 →
Q86VZ1 — 0.969 Q86VZ1 →
Q99PE4 — 0.966 Q99PE4 →
Q76EI6 — 0.955 Q76EI6 →
Q8VCK6 — 0.955 Q8VCK6 →
FFAR2 Free fatty acid receptor 2 0.955 landscape →
GPR35 G-protein coupled receptor 35 0.955 landscape →
Q98907 — 0.953 Q98907 →
P58826 — 0.952 P58826 →
LTB4R Leukotriene B4 receptor 1 0.952 landscape →
P58825 — 0.951 P58825 →
O15529 — 0.951 O15529 →
O93361 — 0.950 O93361 →
Q3UFD7 — 0.950 Q3UFD7 →
Q920E0 — 0.950 Q920E0 →
FFAR3 Free fatty acid receptor 3 0.949 landscape →
A7YY44 — 0.949 A7YY44 →
Q3T181 — 0.948 Q3T181 →
Q99678 — 0.948 Q99678 →
Q5KSK8 — 0.947 Q5KSK8 →
Q8BUD0 — 0.947 Q8BUD0 →
P34996 — 0.946 P34996 →